Board of Directors
Neville Gardiner – Non-Executive Chairman
Richard Lipscombe – Managing Director
Roger Moore – Non-Executive Director
Paul House – Non-Executive Director
Dr Robyn Elliott – Non-Executive Director
Karen Logan – Company Secretary
Mr Neville Gardiner – BBus (Accounting and Business Law)
Mr Gardiner was recently a Partner of Deloitte in its M&A Advisory team. He is a seasoned finance professional with over 30 years’ experience advising Boards of public and private companies on mergers and acquisitions, project development, equity and debt capital markets, transaction structuring, capital allocation and complex commercial problem solving. Prior to Deloitte Mr Gardiner was Co-Founder and Managing Director of Torridon Partners, an independent corporate advisory firm. Torridon Partners was acquired by Deloitte in 2016.
He has held leadership positions at Macquarie Bank, Bank of America Merrill Lynch and Arthur Andersen, and has broad industry sector exposure including health-tech, fin-tech, mining and mining services, infrastructure, energy, and fabrication and construction.
Dr Richard Lipscombe – PhD (London), MA (Oxford)
Richard, a co-founder of the Company, is a highly practised business manager and protein chemist expert in analysing biomolecules using proteomics techniques. He has an extensive expertise in chemistry, immunology, mass spectrometry, peptide synthesis, high performance computing and robotics.
Richard has international experience in both science and business gained over a 30-year period in Australia, USA and the UK, including work in hospital and academic laboratories and commercial organisations. He completed his chemistry degree (MA) at Oxford University, his PhD in immunology at London University and was a Post-Doctoral scientist (molecular immunology) in a large research institution in Australia (Telethon Kids Institute).
After managing the Protein Analysis Facility at the University of Western Australia, he co-founded Proteomics International Pty Ltd in 2001. Richard is well published in peer review journals, and holder of several patents.
Mr Roger Moore – R (Denmark), BPharm (U.Syd)
Roger Moore has 40 years experience in the international pharmaceutical industry, including almost 30 years as President of Novo Nordisk Japan. Mr Moore established Novo’s organisation in Japan as the first employee in 1977, and worked for the company until his retirement as Chairman at the end of 2007. From 2000, Mr Moore was appointed Senior Vice President, Japan and Oceania Region, responsible for Novo Nordisk’s business in Japan, Australia, New Zealand and the Pacific. He was also appointed a member of the Senior Management Board, Novo Nordisk A/S.
In 2007 Mr Moore was awarded the Knight’s Cross of the Order of the Dannebrog by Queen Margrethe II of Denmark.
Since 2008 he has split his time between Australia and Japan and has worked to assist selected Australian biotech companies and selected Japanese pharma companies in their international business development activities.
Mr Paul House – GAICD, BCom (UWA)
Paul House is the current Chief Executive Officer of Imdex Limited, a leading global Mining-Tech company. He previously served eight years as the Managing Director of SGS India, where he was responsible for a workforce of approximately 4,500 personnel across 65 locations in India, including 38 laboratories. SGS is the world’s leading Testing, Inspection and Certification (TIC) company, and operates a network of offices and laboratories in more than 140 countries.
Mr House has previously held Chief Financial Officer and COO roles, and was Senior Manager for several years at a leading global management consultancy firm. Mr House has a track record for delivery of business performance targets, revenue growth, margin improvement, market share and productivity, across multiple services, markets and borders.
Dr Robyn Elliott – BSc (Hons) Chemistry, PhD Inorganic Chemistry
Dr Elliott is Executive Director, Strategic Fractionation Program Delivery within the Global Network Strategy team CSL Behring, a subsidiary of CSL Limited (ASX:CSL). Her role is responsible for business value delivery from a billion dollar global capital expansion portfolio. She is also a non-executive director of PolyNovo Limited (ASX:PNV).
Dr Elliott’s 9 years at CSL Behring have included Senior Director roles for Strategic Expansion Projects and Quality, including supporting the global network strategy team determining the ten-year expansion plan for the CSL Behring global business. Prior to CSL Behring she was Managing Director at IDT Australia Ltd (ASX:IDT) and commenced her career at DBL Faulding.
Dr Elliott has a proven track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Her worldwide experience in new facility delivery, production scale up, strategic planning and governance is of significant benefit to Proteomics International as it drives expansion of its commercial operations.
Karen Logan – BCom, Grad Dip AppCorpGov, FCIS, FGIA, GAICD
Karen has extensive compliance, capital raising, merger and acquisition, IPO and backdoor listing experience in a diverse range of industries including technology, media, resources, health care and life science. She has assisted a substantial number of private start-up and established businesses transition to being publicly-listed companies for over 13 years.
Karen is presently the principal of a consulting firm and secretary of a number of ASX-listed companies, providing corporate and accounting services to those clients.
